Signal transducer and activator of transcription (STAT) family (STAT)

The Signal Transducer and Activator of Transcription (STAT) family consists of seven intracellular proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6) that function as critical mediators of cytokine and growth factor signaling (UniProt, 2024). These proteins are typically activated by Janus kinases (JAKs) through phosphorylation, which triggers their dimerization and translocation into the nucleus to regulate the transcription of genes involved in cell survival, proliferation, and immune responses (StatPearls, 2024). In many pathological conditions, particularly in oncology and autoimmune diseases, STAT signaling becomes constitutively active, driving tumor growth, metastasis, and chronic inflammation (PubMed, 2023). Therapeutic targeting of the STAT family is a major area of drug development, with strategies ranging from direct small-molecule inhibitors of the SH2 domain to antisense oligonucleotides like Danvatirsen that reduce protein expression (NIH, 2023). While many current clinical successes involve indirect modulation via upstream JAK inhibitors, direct STAT3 and STAT5 inhibitors are being investigated to provide more targeted therapy with potentially fewer off-target effects (ClinicalTrials.gov, 2024). However, the pleiotropic nature of STAT signaling across various tissues presents challenges in achieving a favorable therapeutic index and avoiding systemic toxicity (PubMed, 2023).

Other names

STAT proteinsSignal transducers and activators of transcriptionSTAT transcription factors

Direct inhibition of STAT protein dimerization by targeting the SH2 domain, inhibition of DNA binding, or antisense-mediated reduction of STAT mRNA levels; also includes indirect modulation via Janus kinase (JAK) inhibition which prevents STAT phosphorylation (PubMed, 2023; StatPearls, 2024).